GlassScriptPhysician profile
Howard M Karp
NPI 1619986841
$4,235.22
in general payments reported to CMS, 2019-2025
29 companies · $797 in 2025
The $797 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,080 · 2020: $324 · 2021: $70.58 · 2022: $251 · 2023: $801 · 2024: $912 · 2025: $797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,509.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $598.92 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $452.65 | 2019-2025 | Ozempic, Rybelsus, Rivfloza |
| Amgen INC. | $451.90 | 2023-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $409.44 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $348.97 | 2019-2025 | |
| Daiichi Sankyo INC. | $271.57 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $223.79 | 2019-2025 | Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $217.13 | 2023 | |
| Amarin Pharma, INC. | $209.05 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $188.72 | 2023-2024 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $150.09 | 2019-2020 | |
| Pfizer INC. | $143.53 | 2019-2024 | |
| Abbott Laboratories | $98.27 | 2019-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $67.67 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $65.39 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $55.91 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $39.68 | 2019 | |
| Glaxosmithkline, LLC. | $30.19 | 2019-2024 | Trelegy Ellipta |
| Exact Sciences Corporation | $29.70 | 2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $29.62 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $27.27 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $25.99 | 2019-2020 | |
| Phadia US INC. | $21.19 | 2025 | Immunocap |
| Corcept Therapeutics | $17.51 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.23 | 2019 | |
| Janssen Biotech, INC. | $13.14 | 2023 | Tremfya |
| Sanofi Pasteur INC. | $12.35 | 2019 | |
| Medtronic Vascular, INC. | $11.21 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Karp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.